Submitted by Anonymous (not verified) on 27 September 2023 - 13:34
Human medicines European public assessment report (EPAR): Erleada, apalutamide, Prostatic Neoplasms, Date of authorisation: 14/01/2019, Revision: 11, Status: Authorised
Source: